Bessemer Group’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-91,110
| Closed | -$1.98M | – | 1954 |
|
|
2017
Q2 | $1.98M | Sell |
91,110
-189
| -0.2% | -$3.43K | 0.01% | 466 |
|
|
2017
Q1 | $1.28M | Hold |
91,299
| – | – | 0.01% | 637 |
|
|
2016
Q4 | $1.71M | Sell |
91,299
-1,515
| -2% | -$25.8K | 0.01% | 558 |
|
|
2016
Q3 | $1.53M | Buy |
92,814
+1,704
| +2% | +$25.2K | 0.01% | 515 |
|
|
2016
Q2 | $1.23M | Hold |
91,110
| – | – | 0.01% | 443 |
|
|
2016
Q1 | $1.39M | Hold |
91,110
| – | – | 0.01% | 424 |
|
|
2015
Q4 | $1.81M | Hold |
91,110
| – | – | 0.01% | 452 |
|
|
2015
Q3 | $1.59M | Hold |
91,110
| – | – | 0.01% | 473 |
|
|
2015
Q2 | $1.84M | Hold |
91,110
| – | – | 0.01% | 440 |
|
|
2015
Q1 | $1.6M | Hold |
91,110
| – | – | 0.01% | 449 |
|
|
2014
Q4 | $1.48M | Hold |
91,110
| – | – | 0.01% | 423 |
|
|
2014
Q3 | $2.01M | Hold |
91,110
| – | – | 0.01% | 368 |
|
|
2014
Q2 | $1.83M | Hold |
91,110
| – | – | 0.01% | 373 |
|
|
2014
Q1 | $1.69M | Hold |
91,110
| – | – | 0.01% | 369 |
|
|
2013
Q4 | $918K | Hold |
91,110
| – | – | 0.01% | 444 |
|
|
2013
Q3 | $1.18M | Hold |
91,110
| – | – | 0.01% | 386 |
|
|
2013
Q2 | $1.08M | Buy |
+91,110
| New | +$987K | 0.01% | 383 |
|
Other funds holding AMRI
Bessemer Group's AMRI Position: Q3 2017 in Review
Bessemer Group sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 91,110 shares — an estimated $1.98M sold.
Bessemer Group first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $2.01M in Q3 2014. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Bessemer Group reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Bessemer Group sold 91,110 Albany Molecular Research Inc shares in Q3 2017, an estimated $1.98M.
- Bessemer Group first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Bessemer Group's Albany Molecular Research Inc position peaked at $2.01M in Q3 2014.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Bessemer Group's 13F filing for Q3 2017, filed 3 Nov 2017.